+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Angelman syndrome - Market Insights, Epidemiology and Market Forecast-2028

  • ID: 4790886
  • Drug Pipelines
  • February 2019
  • Region: Global
  • 128 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

‘Angelman syndrome - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Angelman syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Angelman syndrome from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2028

Angelman syndrome - Disease Understanding and Treatment Algorithm

According to NORD (National Organization of Rare Disorders), Angelman syndrome is a rare genetic and neurological disorder characterized by severe developmental delays and learning disabilities, absence or near absence of speech, inability to coordinate voluntary movements (ataxia), tremulousness with jerky movements of the arms and legs, a distinctive behavioral pattern characterized by a happy disposition and unprovoked episodes of laughter and smiling, people with Angelman syndrome are usually happy and affectionate and may laugh often and at inappropriate times, affected people may also have epilepsy, is often associated with low levels of pigment in skin, hair and eyes

Individuals affected with the syndrome unable to speak, many gradually learn to communicate through other means such as gesturing. In addition, children may have enough receptive language ability to understand simple forms of language communication. Additional symptoms may occur including seizures, sleep disorders and feeding difficulties. Some children with Angelman syndrome may have distinctive facial features but most facial features reflect the normal parental traits. Angelman syndrome is caused by deletion or abnormal expression of the UBE3A gene. Angelman syndrome occurs when only one copy of the gene is active in certain areas of the brain

The Angelman syndrome market report gives the thorough understanding of the Angelman syndrome by including details such as disease definition, cause, signs and symptoms, complications, genetics, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Angelman syndrome in the US, Europe, and Japan

Angelman syndrome Epidemiology

The Angelman syndrome epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken

The disease epidemiology covered in the report is segmented by Total Prevalent Cases of Angelman syndrome, Live Birth Cases of Angelman syndrome, Adult Prevalent Cases of Angelman syndrome, Diagnosed Prevalent Cases of Angelman syndrome, Angelman syndrome cases by Mutation Types, Angelman syndrome associated Clinical Manifestations

According to this research, the prevalent cases of Angelman syndrome was 58,351 cases in 2017 in 7 MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2017-2028. Among 7MM, United States account for highest prevalent cases of Angelman syndrome with 21,966 prevalent cases in 2017. This trend is expected to increase during the study period

Angelman syndrome Drug Chapters

This segment of the Angelman syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. This report includes detailed chapters of promising upcoming therapies

Angelman syndrome Market Outlook

The Angelman syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight

Angelman syndrome market is expected to grow during the forecasted period of 2019-2028 at a CAGR of XX% owing to the launch of few drugs (presently in Phase III and Phase II). Angelman syndrome therapeutics market has seen a 7MM sales of USD 274.8 Million in 2017

Angelman syndrome Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions

Angelman syndrome Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Angelman syndrome Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Angelman syndrome Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Angelman syndrome market
  • Organize sales and marketing efforts by identifying the best opportunities for Angelman syndrome market
  • To understand the future market competition in the Angelman syndrome market
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

1. KEY INSIGHTS

2. ANGELMAN SYNDROME MARKET OVERVIEW AT A GLANCE
2.1 MARKET SHARE (%) DISTRIBUTION OF ANGELMAN SYNDROME IN 2017
2.2 MARKET SHARE (%) DISTRIBUTION OF ANGELMAN SYNDROME IN 2028

3. DISEASE BACKGROUND AND OVERVIEW
3.1 INTRODUCTION
3.2 CAUSE
3.3 SIGNS AND SYMPTOMS
3.4 RELATED DISORDERS AND DIFFERENTIAL DIAGNOSIS
3.5 COMPLICATIONS
3.5 GENETICS OF ANGELMAN SYNDROME
3.6 MOLECULAR GENETIC PATHOGENESI
3.7 DIAGNOSIS
3.1.1 Clinical criteria for diagnosis
3.1.2 Disease History and Medical Conditions
3.3 DIAGNOSTIC ALGORITHM

4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1 KEY FINDINGS

5. 7MM TOTAL PREVALENT PATIENT POPULATION OF ANGELMAN SYNDROME

6. COUNTRY WISE-EPIDEMIOLOGY OF ANGELMAN SYNDROME
6.1 THE UNITED STATES
6.1.1 Assumptions and Rationale
6.1.2 Total Prevalent Cases of Angelman syndrome in the United States
6.1.3 Live Birth Cases of Angelman syndrome in the United States
6.1.4 Adult Prevalent Cases of Angelman syndrome in the United States
6.1.5 Diagnosed Prevalent Cases of Angelman syndrome in the United States
6.1.6 Angelman syndrome cases by Mutation Types in the United States
6.1.7 Angelman syndrome associated Clinical Manifestations in the United States
6.2 EU5
6.2.1 Assumptions and Rationale
6.3 GERMANY
6.3.1 Total Prevalent Cases of Angelman syndrome in Germany
6.3.2 Live Birth Cases of Angelman syndrome in Germany
6.3.3 Adult Prevalent Cases of Angelman syndrome in Germany
6.3.4 Diagnosed Prevalent Cases of Angelman syndrome in Germany
6.3.5 Angelman syndrome cases by Mutation Types in Germany
6.3.6 Angelman syndrome associated Clinical Manifestations in Germany
6.4 FRANCE
6.4.1 Total Prevalent Cases of Angelman syndrome in France
6.4.2 Live Birth Cases of Angelman syndrome in France
6.4.3 Adult Prevalent Cases of Angelman syndrome in France
6.4.4 Diagnosed Prevalent Cases of Angelman syndrome in France
6.4.5 Angelman syndrome cases by Mutation Types in France
6.4.6 Angelman syndrome associated Clinical Manifestations in France
6.5 ITALY
6.5.1 Total Prevalent Cases of Angelman syndrome in Italy
6.5.2 Live Birth Cases of Angelman syndrome in Italy
6.5.3 Adult Prevalent Cases of Angelman syndrome in Italy
6.5.4 Diagnosed Prevalent Cases of Angelman syndrome in Italy
6.5.5 Angelman syndrome cases by Mutation Types in Italy
6.5.6 Angelman syndrome associated Clinical Manifestations in Italy
6.6 SPAIN
6.6.1 Total Prevalent Cases of Angelman syndrome in Spain
6.6.2 Live Birth Cases of Angelman syndrome in Spain
6.6.3 Adult Prevalent Cases of Angelman syndrome in Spain
6.6.4 Diagnosed Prevalent Cases of Angelman syndrome in Spain
6.6.5 Angelman syndrome cases by Mutation Types in Spain
6.6.6 Angelman syndrome associated Clinical Manifestations in Spain
6.7 THE UNITED KINGDOM
6.7.1 Total Prevalent Cases of Angelman syndrome in the United Kingdom
6.7.2 Live Birth Cases of Angelman syndrome in the UK
6.7.3 Adult Prevalent Cases of Angelman syndrome in the UK
6.7.4 Diagnosed Prevalent Cases of Angelman syndrome in the United Kingdom
6.7.5 Angelman syndrome cases by Mutation Types in the UK
6.7.6 Angelman syndrome associated Clinical Manifestations in the UK
6.8 JAPAN
6.8.1 Assumptions and Rationale
6.8.2 Total Prevalent Cases of Angelman syndrome in Japan
6.8.3 Live Birth Cases of Angelman syndrome in Japan
6.8.4 Adult Prevalent Cases of Angelman syndrome in Japan
6.8.5 Diagnosed Prevalent Cases of Angelman syndrome in Japan
6.8.6 Angelman syndrome cases by Mutation Types in Japan
6.8.7 Angelman syndrome associated Clinical Manifestations in Japan

7. TREATMENT AND MANAGEMENT OF ANGELMAN SYNDROME
7.1 RECOMMENDATIONS FOR THE MANAGEMENT OF ANGELMAN SYNDROME

8. UNMET NEEDS

9. EMERGING THERAPIES
9.1 GABOXADOL: OVID THERAPEUTICS
9.1.1 Product Description
9.1.2 Other Development Activities
9.1.3 Clinical Developmen
9.1.4 Safety and Efficac
9.1.5 Product Profile

10. ANGELMAN SYNDROME: 7 MAJOR MARKET ANALYSIS
10.1 KEY FINDINGS
10.2 MARKET SIZE OF ANGELMAN SYNDROME IN 7MM
10.2.1 Market Size of Angelman syndrome by Therapies

11. MARKET OUTLOOK BY COUNTRY

12. THE UNITED STATES: MARKET OUTLOOK
12.1 UNITED STATES MARKET SIZE
12.1.1 Total Market Size of Angelman syndrome
12.1.2 Market Size of Angelman Syndrome by Therapies

13. EU-5 COUNTRIES: MARKET OUTLOOK
13.1 GERMANY
13.1.1 Total Market size of Angelman syndrome
13.1.2 Market Size of Angelman Syndrome by Therapies
13.2 FRANCE
13.2.1 Total Market Size of Angelman syndrome
13.2.2 Market Size of Angelman Syndrome by Therapies
13.3 ITALY
13.3.1 Total Market Size of Angelman syndrome
13.3.2 Market Size of Angelman Syndrome by Therapies
13.4 SPAIN
13.4.1 Total Market Size of Angelman syndrome
13.4.2 Market Size of Angelman Syndrome by Therapies
13.5 UNITED KINGDOM
13.5.1 Total Market Size of Angelman syndrome
13.5.2 Market Size of Angelman syndrome by Therapies

14. JAPAN: MARKET OUTLOOK
14.1.1 Total Market Size of Angelman syndrome
14.1.2 Market Size of Angelman syndrome by Therapies

15. MARKET DRIVERS

16. MARKET BARRIERS

17. APPENDIX
17.1 REPORT METHODOLOGY

18. Publisher Capabilities

19. DISCLAIMER

20. About the Publisher

List of Tables
Table 1: MOLECULAR GENETIC TESTING USED IN AS AFTER DNA METHYLATION ANALYSIS
TABLE 2: PREVALENT PATIENT POPULATION OF ANGELMAN SYNDROME IN 7MM (2017-2028
TABLE 3: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
TABLE 4: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
TABLE 5: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
TABLE 6: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
TABLE 7: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN THE UNITED STATES (2017-2028)
TABLE 8: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN THE UNITED STATES (2017-2028)
TABLE 9: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
TABLE 10: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
TABLE 11: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
TABLE 12: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
TABLE 13: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN GERMANY (2017-2028)
TABLE 14: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN GERMANY (2017-2028)
TABLE 15: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
TABLE 16: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
TABLE 17: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
TABLE 18: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
TABLE 19: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN FRANCE (2017-2028)
TABLE 20: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN FRANCE (2017-2028)
TABLE 21: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
TABLE 22: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
TABLE 23: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
TABLE 24: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
TABLE 25: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN ITALY (2017-2028)
TABLE 26: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN ITALY (2017-2028)
TABLE 27: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
TABLE 28: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
TABLE 29: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
TABLE 30: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
TABLE 31: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN SPAIN (2017-2028)
TABLE 32: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN SPAIN (2017-2028)
TABLE 33: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED KINGDOM (2017-2028)
TABLE 34: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN THE UK (2017-2028)
TABLE 35: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN THE UK (2017-2028)
TABLE 36: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED KINGDOM (2017-2028)
TABLE 37: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN THE UK (2017-2028)
TABLE 38: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN THE UK (2017-2028)
TABLE 39: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
TABLE 40: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
TABLE 41: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
TABLE 42: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
TABLE 43: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN JAPAN (2017-2028)
TABLE 44: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN JAPAN (2017-2028)
TABLE 45: FEEDING & DIET RECOMMENDATIONS
TABLE 46: DEVELOPMENT RECOMMENDATIONS
TABLE 47: SEIZURE TYPES—THE FOLLOWING ARE TYPICAL OF AS:
TABLE 48: TREATMENT FOR SEIZURES AND CNS
TABLE 49: AGE RECOMMENDATIONS
TABLE 50: AGE RECOMMENDATIONS
TABLE 51: AGE RECOMMENDATIONS
TABLE 52: AGE RECOMMENDATIONS
TABLE 53: AGE RECOMMENDATIONS
TABLE 54: GENERAL HEALTH & ANAESTHESIA RECOMMENDATIONS
TABLE 55: SCOLIOSIS & SKELETAL RECOMMENDATIONS
TABLE 56: PUBERTY & SEXUAL HEALTH RECOMMENDATIONS
TABLE 57: GABOXADOL, CLINICAL TRIAL DESCRIPTION, 2018
TABLE 58: 7 MAJOR MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
TABLE 59: 7 MAJOR MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
TABLE 60: UNITED STATES MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
TABLE 61: THE US MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
TABLE 62: GERMANY MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
TABLE 63: GERMANY MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
TABLE 64: FRANCE MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
TABLE 65: FRANCE MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
TABLE 66: ITALY MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
TABLE 67: ITALY MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
TABLE 68: SPAIN MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
TABLE 69: SPAIN MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
TABLE 70: UNITED KINGDOM MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
TABLE 71: THE UK MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
TABLE 72: JAPAN MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
TABLE 73: JAPAN MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)

List of Figures
Figure 1: IMPRINTING MAP OF PATERNAL AND MATERNAL HUMAN CHROMOSOME 15Q11-13 AROUND AS-1C
FIGURE 2: DIAGNOSTIC ALGORITHM
FIGURE 3: PREVALENT PATIENT POPULATION OF ANGELMAN SYNDROME IN 7MM (2017-2028)
FIGURE 4: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
FIGURE 5: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
FIGURE 6: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
FIGURE 7: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
FIGURE 8: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN THE UNITED STATES (2017-2028)
FIGURE 9: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN THE UNITED STATES (2017-2028)
FIGURE 10: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
FIGURE 11: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
FIGURE 12: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
FIGURE 13: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
FIGURE 14: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN GERMANY (2017-2028)
FIGURE 15: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN GERMANY (2017-2028)
FIGURE 16: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
FIGURE 17: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
FIGURE 18: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
FIGURE 19: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
FIGURE 20: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN FRANCE (2017-2028)
FIGURE 21: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN FRANCE (2017-2028)
FIGURE 22: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
FIGURE 23: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
FIGURE 24: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
FIGURE 25: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
FIGURE 26: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN ITALY (2017-2028)
FIGURE 27: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN ITALY (2017-2028)
FIGURE 28: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
FIGURE 29: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
FIGURE 30: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
FIGURE 31: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
FIGURE 32: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN SPAIN (2017-2028)
FIGURE 33: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN SPAIN (2017-2028)
FIGURE 34: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED KINGDOM (2017-2028)
FIGURE 35: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN THE UK (2017-2028)
FIGURE 36: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN THE UK (2017-2028)
FIGURE 37: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED KINGDOM (2017-2028)
FIGURE 38: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN THE UK (2017-2028)
FIGURE 39: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN THE UK (2017-2028)
FIGURE 40: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
FIGURE 41: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
FIGURE 42: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
FIGURE 43: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
FIGURE 44: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN JAPAN (2017-2028)
FIGURE 45: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN JAPAN (2017-2028)
FIGURE 46: UNMET NEEDS OF ANGELMAN SYNDROME
FIGURE 47: 7 MAJOR MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
FIGURE 48: 7 MAJOR MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
FIGURE 49: MARKET SIZE OF ANGELMAN SYNDROME IN THE UNITED STATES, USD MILLION (2017-2028)
FIGURE 50: THE US MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
FIGURE 51: MARKET SIZE OF ANGELMAN SYNDROME IN GERMANY, USD MILLION (2017-2028)
FIGURE 52: GERMANY MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028
FIGURE 53: MARKET SIZE OF ANGELMAN SYNDROME IN FRANCE USD MILLION (2017-2028)
FIGURE 54: FRANCE MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
FIGURE 55: MARKET SIZE OF ANGELMAN SYNDROME IN ITALY, USD MILLION (2017-2028)
FIGURE 56: ITALY MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
FIGURE 57: MARKET SIZE OF ANGELMAN SYNDROME IN SPAIN, USD MILLION (2017-2028)
FIGURE 58: SPAIN MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
FIGURE 59: MARKET SIZE OF ANGELMAN SYNDROME IN THE UNITED KINGDOM, USD MILLION (2017-228)
FIGURE 60: THE UK MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
FIGURE 61: MARKET SIZE OF ANGELMAN SYNDROME IN JAPAN, USD MILLION (2017-2028)
FIGURE 62: JAPAN MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
FIGURE 63: MARKET DRIVERS
Figure 64: Market Barriers
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • OVID THERAPEUTICS
Note: Product cover images may vary from those shown
Adroll
adroll